Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016

Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016
Published Aug 24, 2016
44 pages — Published Aug 24, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016, provides in depth analysis on Cell Division Protein FtsZ (ftsz) targeted pipeline therapeutics.

The report provides comprehensive information on the Cell Division Protein FtsZ (ftsz), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cell Division Protein FtsZ (ftsz)
- The report reviews Cell Division Protein FtsZ (ftsz) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cell Division Protein FtsZ (ftsz) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cell Division Protein FtsZ (ftsz) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cell Division Protein FtsZ (ftsz)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies &

  
Source:
Document ID
GMDHC0479TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Cell Division Protein FtsZ (ftsz) Overview61
Therapeutics Development73
  Cell Division Protein FtsZ (ftsz) Products under Development by Stage of Development71
  Cell Division Protein FtsZ (ftsz) Products under Development by Therapy Area81
  Cell Division Protein FtsZ (ftsz) Products under Development by Indication91
Cell Division Protein FtsZ (ftsz) Pipeline Products Glance101
  Early Stage Products101
Cell Division Protein FtsZ (ftsz) Products under Development by Companies112
Cell Division Protein FtsZ (ftsz) Products under Development by Universities/Institutes132
Cell Division Protein FtsZ (ftsz) Therapeutics Assessment155
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action161
  Assessment by Route of Administration172
  Assessment by Molecule Type191
Cell Division Protein FtsZ (ftsz) Companies Involved in Therapeutics Development203
  Gero Corp201
  TAXIS Pharmaceuticals, Inc.211
  Vichem Chemie Research Ltd.221
Cell Division Protein FtsZ (ftsz) Drug Profiles2314
  BIZ-20131 Drug Profile231
  BIZ-20132 Drug Profile241
  BIZ-20133 Drug Profile251
  chrysophaentin Drug Profile261
  SBP-17GA20 Drug Profile271
  Small Molecules to Inhibit FtsZ for MRSA Infections Drug Profile281
  Small Molecules to Inhibit FtsZ for Tuberculosis Drug Profile291
  Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections Drug Profile301
  TXA-497 Drug Profile311
  TXA-709 Drug Profile322
  VCC-34236501 Drug Profile341
  VCC-40402101 Drug Profile351
  VCC-59946013 Drug Profile361
Cell Division Protein FtsZ (ftsz) Dormant Projects371
Cell Division Protein FtsZ (ftsz) Featured News &Press Releases385
  Jun 13, 2016: Experimental Antibiotic Treats Deadly MRSA Infection381
  Sep 18, 2015: TAXIS Pharmaceuticals Demonstrates Synergistic Efficacy Against MRSA And Low Resistance Frequency With TXA709/Cefdinir Combination391
  Jun 05, 2015: TAXIS Pharmaceuticals Announces Publication of Data Demonstrating Potential Viability of TXA709 in Combating Antibiotic Resistance401
  Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance412
Appendix432
  Methodology431
  Coverage431
  Secondary Research431
  Primary Research431
  Expert Panel Validation431
  Contact Us431
  Disclaimer441

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016" Aug 24, 2016. Alacra Store. May 14, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cell-Division-Protein-FtsZ-ftsz-Pipeline-Review-H2-2016-2088-16462>
  
APA:
Global Markets Direct - Market Research. (2016). Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016 Aug 24, 2016. New York, NY: Alacra Store. Retrieved May 14, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cell-Division-Protein-FtsZ-ftsz-Pipeline-Review-H2-2016-2088-16462>
  
US$ 3,500.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.